Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Caracciolo

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Leukemia|March 10, 2001
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicityC Tarella, F Zallio, D Caracciolo, et al.
Bone Marrow Transplantation|November 20, 2002
High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilizationC Tarella, M Di Nicola, D Caracciolo, et al.
British Journal of Haematology|December 24, 1997
Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy coursesP Omedè, C Tarella, A Palumbo, et al.
Leukemia|February 18, 2005
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSFI Ricca, M Compagno, M Ladetto, et al.
ESMO Open|April 15, 2022
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysisM A Siciliano, G Caridà, D Ciliberto, et al.
Annals of Hematology|January 5, 2002
High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developmentsC Tarella, A Cuttica, D Caracciolo, et al.
Leukemia|December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaM Ladetto, F Zallio, S Vallet, et al.
HIV Medicine|June 5, 2018
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre studyE Focà, G Cavaglià, S Rusconi, et al.
Leukemia|November 22, 2017
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cellsC Botta, M Cucè, M R Pitari, et al.
Leukemia|June 8, 2007
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)C Tarella, M Zanni, M Di Nicola, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Leukemia|March 10, 2001
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicityC Tarella, F Zallio, D Caracciolo, et al.
Bone Marrow Transplantation|November 20, 2002
High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilizationC Tarella, M Di Nicola, D Caracciolo, et al.
British Journal of Haematology|December 24, 1997
Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy coursesP Omedè, C Tarella, A Palumbo, et al.
Leukemia|February 18, 2005
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSFI Ricca, M Compagno, M Ladetto, et al.
ESMO Open|April 15, 2022
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysisM A Siciliano, G Caridà, D Ciliberto, et al.
Annals of Hematology|January 5, 2002
High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developmentsC Tarella, A Cuttica, D Caracciolo, et al.
Leukemia|December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaM Ladetto, F Zallio, S Vallet, et al.
HIV Medicine|June 5, 2018
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre studyE Focà, G Cavaglià, S Rusconi, et al.
Leukemia|November 22, 2017
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cellsC Botta, M Cucè, M R Pitari, et al.
Leukemia|June 8, 2007
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)C Tarella, M Zanni, M Di Nicola, et al.
Pageof 5